Here’s what you should know:
1. Valeant CEO Joseph Papa said in a release Valeant made the sale to “strengthen our balance sheet.”
2. iNova sold prescription and over-the-counter products for weight management, pain management, cardiology as well as cough and cold medicine.
3. Valeant will continue to sell in markets where iNova is present through its Bausch + Lomb franchise.
4. Valeant will use the $930 million to pay off term loan debt under its senior secured credit facility.
More articles on improving health:
Wisconsin health system expand services through new clinic, provider — 3 insights
XBiotech discontinues phase III study for colorectal cancer antibody therapy — 4 insights
Gastroenterologists ignoring H.pylori guidelines, survey says — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.